Morgan Stanley analyst Matthew Harrison maintained a Buy rating on Argenx Se (ARGX – Research Report) today and set a price target of $401.00. The company’s shares closed last Thursday at $372.97, close to its 52-week high of $387.89.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of 7.3% and a 51.7% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Centessa Pharmaceuticals, Vertex Pharmaceuticals, and Ionis Pharmaceuticals.
Argenx Se has an analyst consensus of Strong Buy, with a price target consensus of $424.00, implying a 9.5% upside from current levels. In a report issued on July 14, J.P. Morgan also maintained a Buy rating on the stock with a $430.00 price target.
The company has a one-year high of $387.89 and a one-year low of $249.50. Currently, Argenx Se has an average volume of 349.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.
Read More on ARGX: